Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the following

RELEVANT EVENT

Grifols has obtained a new long-term loan with the European Investment Bank (EIB) totaling Euros 85 million. Grifols will use this loan to support its R+D+I efforts which are primarily focused on discovering new therapeutic indications for plasma-derived protein therapies.

The financial conditions include a fixed interest rate for a tenor of 10 years and a two-year grace period.

Grifols was among the first European companies to obtain funding through the European Fund for Strategic Investment when it signed its first EIB loan for Euros 100 million in 2015, in 2017 Grifols obtained funding for a second time and today it has reached a third agreement with the EIB within the framework of the Investment Plan for Europe.

In Barcelona, on 7 September 2018

Nuria Martín Barnés
Secretary to the Board of Directors